江西沐邦高科股份有限公司（以下简称"公司"）董事会于近日收到独立董事王婉君女士、非独立董事洪 善建先生的书面辞职报告，具体情况如下： 一、独立董事离任的基本情况 王婉君女士因个人原因，申请辞去公司第五届董事会独立董事职务，同时一并辞去公司审计委员会召集 人职务。辞职后，王婉君女士将不再担任公司任何职务。 证券代码：603398 证券简称：*ST沐邦 公告编号：2026-007 江西沐邦高科股份有限公司 关于公司独立董事、非独立董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 洪善建先生因个人原因，申请辞去公司第五届董事会董事职务，同时一并辞去副董事长职务。辞职后， 洪善建先生将不再担任公司任何职务。 洪善建先生辞去董事职务不会导致公司董事会成员人数低于法定最低人数，其辞职申请自送达公司董事 会之日起生效。洪善建先生已按照公司相关规定做好工作交接。公司将按照有关规定，尽快完成空缺董 事的补选工作。 截至本公告披露日，王婉君女士、洪善建先生均未持有公司股份，亦不存在应当履行而未履行的承诺事 项。公司董事会对王婉君女士 ...

Core Viewpoint - The announcement details a new sales agreement between Invesco Great Wall Fund Management Co., Ltd. and Huaxi Securities Co., Ltd. for the distribution of certain funds starting from February 5, 2026 [1]. Group 1: Applicable Funds - The announcement specifies that certain funds managed by Invesco Great Wall will be available for sale through Huaxi Securities [1]. Group 2: Sales Institution Information - The sales institution is Huaxi Securities Co., Ltd., located in Chengdu, Sichuan, with contact details provided for inquiries [2]. - The legal representative of Huaxi Securities is Yang Jiong Yang, and the contact person is Yang Ru [2]. Group 3: Business Operations - Subscription and redemption services are only available during normal subscription periods and specific open days, with details outlined in the fund's legal documents [3]. - A regular investment plan allows investors to set up automatic deductions for fund purchases, with specific rules governed by Huaxi Securities [3]. Group 4: Fee Structure - Investors may benefit from fee discounts for one-time subscriptions or regular investment plans, subject to the arrangements of Huaxi Securities [4]. - The fund has two classes of shares: Class A, which incurs a subscription fee, and Class C, which does not charge a subscription fee but incurs a service fee [6][7]. Group 5: Redemption Policies - There is no minimum redemption amount, but if a redemption results in a balance of less than one share, the remaining shares must be redeemed [8]. - Redemption fees are applicable and decrease with the holding period of the shares [10]. Group 6: Fund Net Asset Value Disclosure - The fund's net asset value will be disclosed at least weekly during the closed period and no later than the next business day after each open day [11]. Group 7: Additional Information - Investors can access the fund's legal documents, including the fund contract and prospectus, through the company's website or sales institutions for detailed information [12].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:002880 证券简称:卫光生物 公告编号:2026-003 深圳市卫光生物制品股份有限公司 关于对外投资的自愿性披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别风险提示： 1.公司本次与有关合作方共同出资设立项目公司，建设深圳市细胞与基因治疗市场化公共服务平台。公 司认缴出资4,000万元，占项目公司股权比例为40%。认缴出资金额占公司最近一期经审计净资产的比 例为1.81%。 2.项目公司设立后将不纳入公司合并报表范围，并严格按照会计准则的相关规定进行会计核算。本次对 外投资对公司当期财务状况及经营成果不会产生重大不利影响。 深圳市卫光生物制品股份有限公司（以下简称公司）于2026年2月3日召开第四届董事会第七次会议，审 议通过了《关于投资建设深圳市细胞与基因治疗市场化公共服务平台的议案》。现将有关情况公告如 下： 一、对外投资概述 公司拟与深圳市深业生物医药产业发展有限公司（以下简称深业生物）、深圳细胞谷生物医药有限公司 （以下简称深圳细胞谷）及深圳赛桥生物创新技术有限公司（以下简 ...

A股代码：601390 A股简称：中国中铁 公告编号：临2026-011 H股代码：00390 H股简称：中国中铁 中国中铁股份有限公司 第六届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 表决结果：7票同意、0票反对、0票弃权。 （三）审议通过《关于修订〈中国中铁股份有限公司经营开发管理办法〉的议案》。 表决结果：7票同意、0票反对、0票弃权。 一、董事会会议召开情况 中国中铁股份有限公司（以下简称"公司"或"本公司"）第六届董事会第十九次会议〔属2026年第2次临 时会议（2026年度总第2次）〕通知和议案等书面材料于2026年1月21日以专人及发送电子邮件方式送达 各位董事，会议于2026年2月3日以现场会议方式召开。应出席会议的董事7名，实际出席会议的董事7 名。会议由董事长陈文健主持，公司部分高级管理人员及有关人员列席会议。会议的召开符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 二、董事会会议审议情况 经过有效表决，会议审议通过了以下议案： （一）审议通过《关于〈 ...

Core Viewpoint - The announcement details the progress of the controlling shareholder's share freeze release and pledge status, indicating that all shares held by the controlling shareholder, Mr. Li Anmin, have been released from judicial freeze but are fully pledged to a bank for debt guarantees. Share Freeze Release - The controlling shareholder, Mr. Li Anmin, holds 317,807,116 shares, accounting for 31.57% of the company's total share capital, which has been fully released from judicial freeze as of January 4, 2026, following a civil mediation by the Beijing Financial Court [1][2]. Share Pledge Progress - Mr. Li Anmin has pledged all 317,807,116 shares to China Minsheng Bank for the financing of Shanxi Xintai Steel Co., Ltd. The repayment for the principal debt is scheduled to be completed by June 10, 2033, with a total repayment amount of 970.91 million yuan [2]. Non-Operating Fund Occupation - The company previously disclosed an incident where 150 million yuan was paid as a deposit to a target company, which was later returned. This situation constituted a non-operating fund occupation by the controlling shareholder, but the matter has been resolved [3]. Impact of Share Pledge on the Company - The share pledge by the controlling shareholder is not expected to affect the company's main business, financing credit, financing costs, or overall governance [4]. Credit Status of the Controlling Shareholder - Mr. Li Anmin, the controlling shareholder, is the executive director of Shanxi Antai Holding Group Co., Ltd. There are no significant lawsuits or arbitration cases related to debt issues. The core enterprise controlled by him, Xintai Steel, has total assets of 11.752 billion yuan and net assets of 1.658 billion yuan as of September 30, 2025 [4]. Related Transactions - The company has complied with all necessary approval procedures and disclosures regarding daily related transactions and guarantees with Xintai Steel and its subsidiaries [4]. Pledge Risk Assessment - The debt agreement includes provisions for additional collateral if the stock price falls below 1.65 yuan per share. Multiple guarantees are in place to cover the debt, minimizing the risk of forced execution of the pledged shares [5].

Group 1 - The company announced an adjustment to the stock incentive plan for 2025, specifically changing the grant price of restricted stocks from 25.53 yuan per share to 24.53 yuan per share [7][20][21] - The adjustment was made following the implementation of a profit distribution plan, which included a cash dividend of 10.00 yuan per 10 shares [5][8] - The adjustment method for the grant price is based on the formula P = P0 - V, where P0 is the original grant price and V is the dividend per share [6][8] Group 2 - The company held a board meeting on February 4, 2026, where the adjustment to the stock incentive plan was approved, along with the granting of reserved restricted stocks [4][32] - The reserved grant date was set for February 4, 2026, with a total of 134,000 shares to be granted to 16 incentive targets at the adjusted price of 24.53 yuan per share [28][37] - The company confirmed that the granting conditions for the incentive plan have been met, and the process followed legal and regulatory requirements [36][48] Group 3 - The company plans to provide a guarantee of up to 20 million yuan for its wholly-owned subsidiary to support its daily operations and development [13][14] - The board approved this guarantee on February 4, 2026, and it does not require shareholder approval [14][18] - The total amount of guarantees provided by the company, including this new guarantee, represents 1.17% of the company's latest audited net assets [18]

■ 内蒙古蒙电华能热电股份有限公司 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意内蒙古蒙电华能热电股份有限公司发行股份购买资产并 募集配套资金注册的批复》（证监许可〔2025〕3031号），同意内蒙古蒙电华能热电股份有限公司（以 下简称"公司"）发行股份募集配套资金不超过265,000万元的注册申请。 公司本次募集配套资金发行股份536,437,246股，每股发行价人民币4.94元，募集资金总额为人民币 2,649,999,995.24元，扣除不含税的发行费用人民币5,711,337.46元，公司募集资金净额为人民币 2,644,288,657.78元，其中计入股本人民币536,437,246.00元，计入资本公积人民币2,107,851,411.78元。 上述资金到位情况已经由中证天通会计师事务所（特殊普通合伙）审验，并出具了《验资报告》（中证 天通（2026）验字21100003号）。 二、募集资金专户开设情况 公司于 2026年1月13日召开第十一届董事会第二十一次会议，审议并批准了《关于开设募集资金专项账 户并授权签署募集资金监管协议、办理开户等事宜的议案》，同意公司在中国工商银行 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000403 证券简称：派林生物 公告编号：2026-002 药物名称：人凝血因子IX 剂型：注射剂 规格：500IU/瓶，复溶后10ml 申请事项：境内生产药品注册上市许可 申请人：广东双林生物制药有限公司 派斯双林生物制药股份有限公司 关于全资子公司获得药品注册上市许可受理通知书的公告 本公司及董事会全体成员保证信息披露的内容的真实、准确和完整，没有虚假记载、误导性陈述或者重 大遗漏。 近日，派斯双林生物制药股份有限公司（以下简称"公司"）之全资子公司广东双林生物制药有限公司 （以下简称"广东双林"）收到国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通 知书》（受理号：XCSS2600002），现将有关情况公告如下： 一、药品基本情况 五、风险提示 公司已获得人凝血因子IX药品注册上市许可《受理通知书》，具体审批完成时间尚不确定，公司将按 照国家有关规定，积极推进上述研发项目，将根据后续进展情况及时履行信息披露义务，敬请广大投资 者注意投资风险。 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以受理。 ...

Core Viewpoint - The company has announced adjustments to the stock option exercise prices for its 2024 and 2025 stock option and restricted stock incentive plans, which were approved by the board of directors and the compensation and assessment committee [8][13][17]. Group 1: Approval Procedures - The company held multiple board and supervisory meetings to review and approve the stock option and restricted stock incentive plans for 2024 and 2025, ensuring compliance with relevant regulations [1][9][10]. - The company conducted internal public announcements regarding the initial grant of incentive objects, with no objections received during the public notice period [2][3][11]. Group 2: Adjustment Details - The adjustments to the exercise prices were necessitated by the company's profit distribution plan, which includes a cash dividend of 0.50 yuan per 10 shares for the first three quarters of 2025 [14]. - The adjusted exercise prices for the 2024 stock options are 7.77 yuan for the first grant and 6.36 yuan for the reserved grant, while for the 2025 stock options, they are 6.52 yuan for the first grant and 7.00 yuan for the reserved grant [16]. Group 3: Impact and Compliance - The adjustments to the exercise prices are not expected to have a substantial impact on the company's financial condition or operational results, and the management team will continue to fulfill its responsibilities diligently [16][17]. - The adjustments have been deemed compliant with relevant laws and regulations, ensuring that there is no harm to the interests of the company's shareholders [17][18].

Meeting Overview - The first temporary shareholders' meeting of Shandong Expressway Bridge Group Co., Ltd. was held on February 4, 2026, combining on-site and online voting methods [4][5]. - The meeting was chaired by Chairman Lin Cunyou and complied with relevant laws and regulations [5][20]. Attendance - A total of 266 shareholders and authorized representatives attended the meeting, representing 989,389,023 shares, which is 64.1094% of the total voting shares [6]. - Among them, 4 shareholders attended the on-site meeting, representing 976,450,917 shares (63.2711% of total voting shares) [7]. - 262 shareholders participated via online voting, representing 12,938,106 shares (0.8384% of total voting shares) [8]. - Small and medium shareholders totaled 263, representing 12,981,206 shares (0.8411% of total voting shares) [9]. Resolutions and Voting Results - The meeting adopted a combination of on-site and online voting for the resolutions [10]. - The following resolutions were passed: - Approval of the estimated 2026 annual related party transactions [11][12]. - Revision of the "Independent Director Work System" [13]. - Revision of the "Independent Director Special Meeting Work System" [14]. - Revision of the "Related Party Transaction System" [15]. - Revision of the "Financial Management System" [16]. - Revision of the "External Guarantee System" [17]. - Revision of the "External Investment System" [18][19]. - Revision of the "Internal Audit System" [20]. - Revision of the "Director and Senior Management Compensation Management System" [20]. Legal Opinion - The legal opinion was provided by Guohao Law Firm (Jinan), confirming that the meeting's procedures, qualifications of attendees, and voting results complied with relevant laws and regulations [20].